Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 25 Aug 2023
United States: Lorazepam (LOR) stimulates fibrosis and inflammatory signaling, promotes ischemic, and is linked to a lower survival rate for pancreatic cancer.
Read Full NewsComplicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.
A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.
The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.
1.
Remote monitoring can improve recovery from cancer surgery
2.
Radiation therapy can promote amphiregulin, which increases growth of metastases
3.
For cancer patients who are not responding to chemotherapy, new genes and natural toxins offer hope.
4.
DNA origami offers more accurate imaging in the fight against pancreatic cancer
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Colon Cancer Staging: What You Need to Know
2.
Exploring the Potential of Xospata: A New Frontier in Cancer Treatment
3.
Understanding QSOFA: A Vital Tool for Recognizing Sepsis
4.
Everything You Need to Know About HTLV: A Comprehensive Guide
5.
Uncovering the Mysteries of the RDW Blood Test
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part III
2.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
4.
Understanding the causes of anemia in adults beyond nutritional deficiencies
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge